Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Merck
McKinsey
Dow
Colorcon

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020919

See Plans and Pricing

« Back to Dashboard

NDA 020919 describes GEODON, which is a drug marketed by Pfizer and Pfizer Inc and is included in three NDAs. It is available from three suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the GEODON profile page.

The generic ingredient in GEODON is ziprasidone mesylate. There are twenty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ziprasidone mesylate profile page.
Summary for 020919
Tradename:GEODON
Applicant:Pfizer
Ingredient:ziprasidone mesylate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020919
Suppliers and Packaging for NDA: 020919
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919 NDA Roerig 0049-1203 0049-1203-10 10 CARTON in 1 CARTON (0049-1203-10) > 1 VIAL, SINGLE-DOSE in 1 CARTON (0049-1203-01) > 1 mL in 1 VIAL, SINGLE-DOSE
GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919 NDA Roerig 0049-3920 0049-3920-83 10 VIAL, SINGLE-DOSE in 1 CARTON (0049-3920-83) > 1 mL in 1 VIAL, SINGLE-DOSE (0049-3920-20)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAMUSCULARStrengthEQ 20MG BASE/ML
Approval Date:Jun 21, 2002TE:RLD:Yes

Expired US Patents for NDA 020919

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002   Start Trial   Start Trial
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002   Start Trial   Start Trial
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002   Start Trial   Start Trial
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002   Start Trial   Start Trial
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002   Start Trial   Start Trial
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Mallinckrodt
Colorcon
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.